NAR Cancer paper in Collaboration with the Roberts lab
A recent collaboration with the Roberts lab has been published in NAR Cancer, revealing that disruption of the cell’s ubiquitin-proteasome system, achieved through FDA-approved drugs for cancer treatment, elevates APOBEC3A levels in breast cancer and multiple myeloma cells. APOBEC3A, known for its role as a cytidine deaminase, is associated with APOBEC-induced mutations observed across various […]